16
Participants
Start Date
October 11, 2018
Primary Completion Date
December 15, 2023
Study Completion Date
December 15, 2028
Brentuximab Vedotin
Brentuximab Vedotin will be given at 1.8 mg/kg IV over approximately 30 minutes on D1 every 21 days for 2-6 cycles. Responders (CR, PR or SD) who are not eligible for bone marrow transplant (BMT) and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV for approximately 30 minutes, every 21 days).
CHEP
"Cyclophosphamide- 750 mg/m\^2 IV over approximately 1 hour on D1 every 21 days for 2-6 cycles~Doxorubicin- 50 mg/m\^2 IV over approximately 3-5 minutes on D1 every 21 days for 2-6 cycles.~Etoposide - 100 mg/m\^2 IV over approximately 1 hour each day for 3 days every 21 days for 2-6 cycles.~Prednisone - 100 mg, orally once daily for 5 days every 21 days for 2-6 cycles."
Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill, Chapel Hill
South Broward/Memorial Healthcare System, Hollywood
Boston Medical Center, Boston
Beth Israel Deaconess Medical Center (BIDMC), Boston
Seagen Inc.
INDUSTRY
UNC Lineberger Comprehensive Cancer Center
OTHER